Vabysmo is a bispecific antibody designed to inhibit vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2).
STAT6 degradation is expected to provide a clinical benefit for patients with Type 2 inflammatory diseases, including asthma.
The authors updated a diagnosis list to identify low-acuity emergency department visits by veterans and applied it to examine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results